The purpose of the study was to examine the yield of CD34 þ cells, response rates, and toxicity of high-dose cyclophosphamide with or without etoposide in patients with multiple myeloma. In total, 77 myeloma patients received either cyclophosphamide 4.5 g/m 2 (n ¼ 28) alone or with etoposide 2 g/m 2 (n ¼ 49) in a nonrandomized manner, followed by G-CSF 10 lg/kg/day for the purpose of stem cell mobilization. The effects of various factors on CD34 þ cell yield, response rate and engraftment were explored. A median of 22.39 Â 10 6 CD34 þ cells/kg were collected on the first day of leukapheresis (range 0.59-114.71 Â 10 6 /kg) in 71 (92%) of patients. Greater marrow plasma cell infiltration (P ¼ 0.02) or prior radiation therapy (P ¼ 0.02) adversely affected CD34 þ cell yield. In total, 45% of patients receiving cyclophosphamide and 56% of those receiving cyclophosphamide/etoposide had at least a minimum response by EBMT criteria. In all, 25% of patients who received cyclophosphamide alone vs 75.5% of patients who received combined chemotherapy required hospitalization mainly for treatment of neutropenic fever. Cyclophosphamide alone is associated with impressive CD34 þ cell yields and clear antimyeloma activity. The addition of etoposide resulted in increased toxicity without significant improvement in CD34 þ cell yield or response rates. High-dose chemotherapy and autologous hematopoietic stem cell transplantation (ASCT) results in higher response rates and longer disease-free and overall survival in selected patients with multiple myeloma (MM) when compared to standard-dose chemotherapy, without increase in treatment-related mortality rate.
The purpose of the study was to examine the yield of CD34 þ cells, response rates, and toxicity of high-dose cyclophosphamide with or without etoposide in patients with multiple myeloma. In total, 77 myeloma patients received either cyclophosphamide 4.5 g/m 2 (n ¼ 28) alone or with etoposide 2 g/m 2 (n ¼ 49) in a nonrandomized manner, followed by G-CSF 10 lg/kg/day for the purpose of stem cell mobilization. The effects of various factors on CD34 þ cell yield, response rate and engraftment were explored. A median of 22.39 Â 10 6 CD34 þ cells/kg were collected on the first day of leukapheresis (range 0.59-114.71 Â 10 6 /kg) in 71 (92%) of patients. Greater marrow plasma cell infiltration (P ¼ 0.02) or prior radiation therapy (P ¼ 0.02) adversely affected CD34 þ cell yield. In total, 45% of patients receiving cyclophosphamide and 56% of those receiving cyclophosphamide/etoposide had at least a minimum response by EBMT criteria. In all, 25% of patients who received cyclophosphamide alone vs 75.5% of patients who received combined chemotherapy required hospitalization mainly for treatment of neutropenic fever. Cyclophosphamide alone is associated with impressive CD34 þ cell yields and clear antimyeloma activity. The addition of etoposide resulted in increased toxicity without significant improvement in CD34 þ cell yield or response rates. High-dose chemotherapy and autologous hematopoietic stem cell transplantation (ASCT) results in higher response rates and longer disease-free and overall survival in selected patients with multiple myeloma (MM) when compared to standard-dose chemotherapy, without increase in treatment-related mortality rate.
1,2 Tandem transplants, supported by either autologous bone marrow or peripheral blood progenitor cell (PBPC) infusions, have been found to be feasible, however, the actual impact of this strategy on disease-free and overall survival, and its superiority to a single transplant for the treatment of myeloma needs further evaluation. [2] [3] [4] Several studies in the area of progenitor cell mobilization suggest that fairly intensive chemotherapy followed by hematopoietic growth factors results in the collection of more progenitor cells than growth factor administration alone (reviewed in Olavarria and Kanfer 5 ). By using drugs that are active against myeloma, mobilization treatment might therefore be used for the dual purpose of providing ample progenitor cells and tumor bulk reduction, prior to ASCT. Although the contribution of pre-ASCT disease bulk reduction has not been studied systematically, the results of tandem transplant programs suggest that it is likely to be beneficial. 2, 3 While cyclophosphamide and etoposide containing regimens have been studied for their mobilization potential, different doses and schedules have been used in the various studies. In addition, the methods of progenitor cell harvesting (date of leukapheresis, volume processed, cell separator used) vary from study to study. Few of these studies included a large number of myeloma patients. Moreover, in most of the studies, patients were not formally re-staged prior to ASCT, so that response rates are not well known.
We analyzed data from a series of MM patients who received mobilization therapy consisting of cyclophosphamide with or without etoposide followed by granulocyte colonystimulating factor (G-CSF), in order to define the response rates and mobilization effectiveness of this treatment. We also analyzed the effects of various pre-mobilization factors on the yield and response rates achieved with mobilization, and on the pace of engraftment following ASCT.
Patients and methods

Patients
Between September 1997 and March 2000, 77 consecutive patients with MM received mobilization chemotherapy in order to obtain hematopoietic stem cells for University of Maryland School of Medicine, Institutional Review Board approved ASCT treatment protocols. Eligible patients had confirmed MM, aged 18-75 years, and were required to have adequate organ function as reflected in a left ventricular ejection fraction of more than 50% by echocardiogram or MUGA scan, forced expiratory volume in 1 s and diffusion capacity of carbon monoxide more than 50% of the predicted value, serum creatinine p3.0 mg/dl and serum direct bilirubin p2.0 mg/dl. Patients were required to have Southwest Oncology Group (SWOG) performance status of 2 or less, unless poor performance status was due to bone pain. All patients seen at our institution during the time period who were eligible according to above criteria were offered ASCT. No patients were excluded based on disease stage or number of prior treatments. The immediate pre-mobilization chemotherapy depended on the time the patients were first seen at our center, their most recent treatment and the disease status. We tried to use less intense pre-mobilization treatment such as 2 months of dexamethasone pulsing (dexamethasone 40 mg orally on days 1-4, 9-12, 17-20) and then tried to maximize the intensity of mobilization chemotherapy by giving high-dose cyclophosphamide with or without etoposide.
Mobilization chemotherapy, collection of PBPCs, and supportive care
Mobilization was attempted in all patients who were eligible for ASCT. The mobilization regimen consisted of cyclophosphamide 4.5 gm/m 2 intravenous (I.V.) infusion over 12 h on day 1 (28 patients), along with mesna 4.5 g/m 2 i.v. infusion over 18 h. Forty-nine other patients received the same regimen followed the next day by etoposide 2 g/m 2 i.v. infusion over 6 h. The inclusion of etoposide was not due to patient randomization. Instead, prior to 11/01/1998, etoposide was not given to those patients who were felt to have low-risk disease or who might not tolerate its addition. After that period, all patients received both cyclophosphamide and etoposide. Antiemetics and intravenous hydration were given routinely. Patients were discharged home after completion of chemotherapy and followed in an outpatient clinic setting, while receiving subcutaneous injections of recombinant human G-CSF at a dose of 10 mg/kg/day (corrected to nearest 300 or 480 mg vial), starting within 24-72 h after chemotherapy. Prophylactic medications included ciprofloxacin 500 mg by mouth twice daily, or levofloxacin 500 mg by mouth daily until neutrophil recovery. In addition, all patients received oral fluconazole 200 mg once a day and famcyclovir 500 mg twice a day until neutrophil recovery. Complete blood counts were measured at least every other day. When the total leukocyte count reached 2 Â 10 9 /l or more, circulating CD34 þ cell counts were measured daily or every other day using flow cytometry (ProCOUNT, Becton Dickinson, San Jose, CA, USA). Leukapheresis was begun when the CD34 þ cell count exceeded 20/ml or was felt to have peaked. Six patients, whose circulating CD34 þ cell count never reached this value were considered to have failed mobilization. These patients were subsequently treated with G-CSF 10 mg/kg/day plus granulocyte-macrophage (GM)-CSF 250 mg/m 2 /d after a 3-week rest period, for a second mobilization attempt. Large volume leukapheresis (15-30 L over 2-5 h) was employed, using the COBE Spectra (Gambro BCT, Lakewood, CO, USA) continuous flow cell separator in the manual PBSC mode. The CD34 þ progenitor cell content of apheresis product was measured by a dual platform (ISHAGE) flow-cytometric method. As the ASCT protocol was designed to deliver several cycles of post-transplant consolidation chemotherapy, leukapheresis was repeated if necessary, in order to obtain a target of more than 10 Â 10 6 CD34 þ cells/kg so that back-up cells could be stored. Stem cells were cryopreserved in 10% dimethylsulfoxide (DMSO) in liquid nitrogen freezers (À1801C) following a controlled freezing procedure.
All patients who developed febrile neutropenia were hospitalized for treatment, and all patients were supported with irradiated blood components. Platelets (single donor, apheresis platelets) were transfused prophylactically for a platelet count o20 Â 10 9 /l or at a higher level for clinical indications, and packed red blood cells were given for hemoglobin o8.0 g/dl or symptomatic anemia.
ASCT conditioning regimen
The transplant conditioning regimen consisted of carmustine 300 mg/m 2 i.v. infusion over 2 h on day À2 and melphalan 140 mg/m 2 over 20 min i.v. infusion on day -1. Gemcitabine 1 g/m 2 was given i.v. over 100 min on day À5 and again 6 h after the administration of carmustine on day À2 to patients who were more than 12 months from initial diagnosis (15 patients). Stem cells were infused on day 0. In all patients G-CSF (5 mg/kg/day) was started on day þ 4 and continued until absolute neutrophil count (ANC) recovered to 10 9 /l for 2 consecutive days.
Assessment of mobilization effectiveness, responses, and engraftment
Mobilization success was measured by the peak number of circulating CD34 þ progenitor cells, and the number of CD34 þ cells/kg collected on the first day of leukapheresis, both treated as continuous variables. Myeloma burden was assessed by quantitative measures of myeloma protein in serum and urine (electrophoresis and immunofixation), and bone marrow (BM) aspiration for plasma cell counts. These measurements were performed immediately prior to mobilization and prior to ASCT. Response rates were defined according to common criteria proposed by the EBMT, IBMTR and ABMTR, 6 however, since the patients proceeded to transplant immediately after mobilization, the second set of measurements required by above criteria to confirm responses could not be obtained. Engraftment after ASCT was assessed by the time required to recover neutrophils 40.5 Â 10 continuous variables on the mobilization effectiveness and engraftment kinetics following ASCT were evaluated by Pearson correlation coefficient; the effects of other variables on mobilization effectiveness and engraftment kinetics were assessed using t-test and one-way ANOVA.
Stepwise regression model was applied on multivariate analysis to select variables predictive of outcomes with specified statistical significance level. The influence of various pre-treatment factors on response rates was analyzed by w 2 test and Fisher's exact test. Confidence intervals (CIs) for response rates were calculated using the exact binomial method. All statistical analyses required a significance level of 0.05. Nominal or categorical variables were mobilization regimen (cyclophosphamide or cyclophosphamide plus etoposide), sex (male vs female), LDH (normal or elevated), type of myeloma (Ig G, A or other), bone marrow cytogenetics (abnormality of chromosome 11 or 13, other cytogenetic abnormalities, normal), stage (Durie-Salmon I, II, or III), previous treatment with melphalan, interferon, or external beam radiation, response to most recent therapy (responsive versus refractory), response (by EBMT criteria), and conditioning regimen (with or without gemcitabine). All other factors were treated as continuous variables.
The following variables were analyzed for their effects on the mobilization yield, response rates after mobilization therapy, and engraftment after ASCT: age, sex, type of MM, disease stage, LDH, b 2 -microglobulin level, CRP level, pre-mobilization platelet count, number of months since diagnosis, number of months since start of therapy, number of months of previous therapy, number of prior therapeutic regimens, previous treatment with melphalan, interferon, or external beam radiation, percentage plasma cells in BM prior to mobilization and mobilization regimen. Additional variables analyzed for their effect on mobilization yield were number of days between cyclophosphamide infusion and leukapheresis and number of days to neutrophil (ANC 40.5 Â 10 9 /l) or platelet (420 Â 10 9 /l) recovery after mobilization therapy. In addition, disease responsiveness prior to mobilization and cytogenetics were examined for their effect on response, and the number of CD34 þ cells/kg infused at the time of transplant and the type of transplant conditioning regimen (with or without gemcitabine) were analyzed for their effect on time to neutrophil and platelet recovery following transplant.
Results
Patient characteristics
A total of 77 patients were treated, 28 of whom received cyclophosphamide alone while 49 received cyclophosphamide and etoposide. Patient characteristics are described in Table 1 . Patient characteristics were compared between the two groups by the t-test and Wilcoxon rank sums test for continuous variables and w 2 test or Fisher's exact test for categorical variables. Although the trial is not randomized, all variables tested between the two groups did not reach the 0.05 significance level.
Overall, 13 patients in both groups received prior radiation therapy (range 2000-4500 cGy): spinal irradiation only (seven patients), spinal/pelvic/sacral irradiation (four patients; three of whom received irradiation to long bones as well), pelvic/sacral irradiation only (one patient) and irradiation to long bones only (one patient). In the cyclophosphamide only group, immediate pre-mobilization treatment consisted of dexamethasone only (14 patients, median two cycles, range 1-2), VAD (11 patients, median four cycles, range 2-7), and melphalan/prednisone (one patient, four cycles). In the cyclophosphamide/etoposide group, immediate pre-mobilization treatment consisted of dexamethasone (25 patients, median two cycles, range 1-3), VAD (14 patients, median four cycles, range 2-6), melphalan/prednisone (one patient three cycles and one patient six cycles), and other chemotherapy (three patients). At the time of mobilization, seven (25%) patients in the cyclophosphamide group were in complete remission (CR), 10 (35.5%) had partial remission (PR), two (7%) patients had minimal response (MR), five (18%) patients had stable disease (SD), three (11%) had progressive disease (PD) and one (3.5%) patient was incompletely restaged. In the cyclophosphamide/etoposide group, four (8%) patients were in CR, 15 (31%) patients had PR, nine (18.5%) patients had MR, seven (14%) patients had s.d., and 14 (28.5%) patients had PD.
Mobilization effectiveness
The results of mobilization are described in Table 2 þ cells/kg) after receiving G-CSF plus GM-CSF following a 3-week rest period. When comparison between the two groups was performed (Wilcoxon rank sum test), the only statistically significant difference was observed in the median number of days from the start of chemotherapy to first leukapheresis (P ¼ 0.0005; Table 2 ).
The patients who were considered mobilization failures (and did not undergo leukapheresis) were assigned number 0 and included in the statistical analysis of factors affecting CD34 þ cell yield. In univariate analysis, the number of CD34 þ cells collected on the first day of leukapheresis strongly correlated with the circulating CD34 þ cell count (Po0.001), and negatively correlated with the number of days until leukapheresis (P ¼ 0.02), neutrophil recovery (P ¼ 0.006), and platelet recovery (P ¼ 0.006) following mobilization chemotherapy. The number of months from initial diagnosis (P ¼ 0.017), number of months since start of therapy (P ¼ 0.004), number of months of treatment received (P ¼ 0.018), number of prior therapeutic regimens (P ¼ 0.008), percentage of bone marrow plasma cells (P ¼ 0.005), and prior use of melphalan (Po0.001) or irradiation (P ¼ 0.029) also negatively correlated with the number of CD34 þ cells collected on the first day of leukapheresis. Higher pre-mobilization platelet count positively correlated with the number of CD34 þ cells collected on the first day of leukapheresis (P ¼ 0.007). The type of mobilization regimen used was not associated with the number of CD34 þ cells collected on the first day of leukapheresis (P ¼ 0.68). On multivariate regression analysis, only the percentage of bone marrow plasma cells (P ¼ 0.02) and the prior receipt of radiation therapy (P ¼ 0.02) were found to be negatively associated, while the prior administration of melphalan was marginally associated (P ¼ 0.053) with the number of CD34 þ progenitor cells collected on the first day of leukapheresis. 
Response rates
Of the 28 patients who received cyclophosphamide alone, seven were already in CR prior to mobilization. One patient did not have complete pre-mobilization staging. Thus, 20 patients were evaluable for response. Responses included three (15%) CR, one (5%) PR, five (25%) MR, 10 (50%) SD, and one (5%) PD. The overall objective response rate (CR þ PR þ MR) was 45% (95% CI 23.1-68.5%). The small number of evaluable patients in this group did not permit an analysis of factors predictive of response. In this group of patients, the median % BM involvement with plasma cells decreased from 6.25 (range 0-75) pre-mobilization to 2 (range 0-11) post-mobilization. However, the median % reduction (change) in BM involvement with plasma cells is 3 (range -2.5-58).
In the cyclophosphamide plus etoposide group, four patients were already in CR at the time of mobilization. Thus, 45 patients were evaluable for response: eight (17.8%) achieved CR, 11 (24.5%) achieved PR, six (13.3%) achieved MR, 16 (35.5%) had SD, and four (8.9%) had PD. The overall objective response rate (CR þ PR þ MR) was 55.6% (95% CI, 40.0-70.4%). In this group of patients, the sole factor predictive of better response was type of myeloma (P ¼ 0.015). Patients with other types of myeloma had better response than patients with IgA type, and patients with IgG type of myeloma did worse. All other factors analyzed were found not to be predictive of response with p-values greater than 0.05. The observed difference in the objective response rates (CR þ PR þ MR) between the two groups of patients is 10.6% which is not statistically significant (p ¼ 0.46). Although the % of patients who achieved either CR or PR was higher in the cyclophosphamide/etoposide group (19 patients; 42.3%) than in the cyclophosphamide only group (four patients; 20%), the difference was not found to be statistically significant as well (P ¼ 0.08). In the cyclophosphamide/etoposide group, median % BM plasma cell involvement decreased from 10 (range 0-90) premobilization to 3 (range 0-90) post-mobilization. The median % reduction (change) in BM involvement with plasma cells is 3.5 (range -15.5 to 79.5), and when compared with the cyclophosphamide only group was not found to be statistically significant (P ¼ 0.96; Wilcoxon rank sum test).
We also analyzed the entire group of patients for response rates. The total 65 patients were evaluable for response and 34 of them achieved objective response (CR þ PR þ MR). The overall objective response rate is 52.3% (95% CI, 39.5-64.9%). Same as for the cyclophosphamide/etoposide group, the sole factor predictive of better response was type of myeloma (P ¼ 0.01). Again patients with other types of myeloma had better response than patient with IgA type, while patients with IgG type did worse.
Toxicity of mobilization therapy. The toxicity data for each group are summarized in Table 3 .
Engraftment following ASCT
All 77 patients subsequently received ASCT. The results are shown in Table 4 . The mean number of CD34 þ cells infused was 9.91 Â 10 6 /kg (SD 7.41 Â 10 6 /kg). Neutrophil recovery 40.5 Â 10 9 /l occurred at a median of 12 days (range 6-48 days), and platelet recovery 420 Â 10 9 /l at 14 days (range 0-141 days) after ASCT. By univariate analysis, none of the factors analyzed showed a significant correlation with the time to neutrophil or platelet count recovery (P-values 40.05).
Discussion
It is now known that high-dose chemotherapy with autologous progenitor cell support is associated with improvement in disease-free interval and overall survival rates for patients with MM, as compared with conventional chemotherapy.
1,2 The benefit of high-dose therapy appears to be maintained whether it is applied early or late after the diagnosis of myeloma. 7 The use of peripheral blood stem cells has been associated with earlier hematopoietic recovery after transplant and lower transfusion needs than steady-state bone marrow. 8 Studies show that progenitor cell yields with chemotherapy plus growth factor are higher than with growth factor alone. [9] [10] [11] As engraftment times are dependent on the number of progenitor cells infused, many centers favor the use of chemotherapy plus growth factor, Table 3 Major toxicities
Cyclophosphamide Cyclophosphamide/ etoposide despite the greater variability in predicting the optimal day to start leukapheresis. Moreover, since single autologous transplants are generally not curative in myeloma, there is interest in obtaining more than the required number of progenitor cells for a single transplant, and to store backup cells for a second transplant or for post-transplant chemotherapy support. The latter reason motivated us to adopt a chemotherapy plus growth factor approach for the mobilization of our patients undergoing autologous transplant. We also hoped that by using drugs active against myeloma, the mobilization therapy might provide some reduction in disease burden prior to the high-dose transplant therapy, thereby potentially improving the overall treatment results. Our method of graft collection, that is, tracking of circulating CD34 þ cells followed by large volume leukapheresis, was also designed to optimize the yield of CD34 þ progenitor cells while minimizing the days of leukapheresis and thereby costs. The study was not designed to evaluate whether this approach would reduce the degree of graft contamination by myeloma cells.
Both regimens used in this study resulted in a large proportion of patients (91%) being able to have sufficient CD34 þ progenitor cells (45 Â 10 6 /kg) collected by leukapheresis. Six patients in whom this procedure failed were subsequently collected after using high-dose G-plus GM-CSF alone, following a 3-week rest period. Moreover, 45 Â 10 6 /kg CD34 þ progenitor cells were collected by the first leukapheresis procedure alone in 81% of patients. In the cyclophosphamide plus etoposide group, 47/49 patients (96%) were able to achieve 420/ml circulating CD34 /day Â 3) followed by G-CSF achieved the target level of 5 Â 10 6 CD34 þ cells/kg in a median of two (range 1-8) collections, and were able to be transplanted with PBSC alone. In contrast, only 6/14 (43%) of patients who had received cyclophosphamide with either G-CSF (n ¼ 7) or GM-CSF (n ¼ 7) in a prior study at the same institution achieved a similar target, requiring a median of 4 (range 2-6) leukapheresis. The authors therefore concluded that the likelihood of achieving 5 Â 10 6 CD34 þ cells/kg was higher with cyclophosphamide plus etoposide than cyclophosphamide alone (P ¼ 0.02), although patients were not assigned randomly. However, their group of myeloma patients is different from ours, since all patients in their study had progressive or refractory disease and had received a median of 8 (cyclophosphamide group) or 10 (cyclophosphamide/etoposide group) chemotherapy cycles prior to mobilization. Furthermore, the doses of cyclophosphamide and etoposide were different. Our patients were less heavily pretreated and had received a median of 4 (cyclophosphamide group) or 2 (cyclophosphamide/etoposide group) premobilization chemotherapy cycles, which could be an explanation for a good progenitor cell collection observed in both groups. All six patients who failed mobilization in our study were heavily pretreated having received more than 12 months of chemotherapy prior to mobilization. Of total five heavily pretreated patients in cyclophosphamide only group, only one patient was successfully mobilized (four failures), while of total five heavily pretreated patients in cyclophosphamide/etoposide group three patients were successfully mobilized (two failures). These numbers are too small to draw conclusion about any differences in efficacy. Goldschmidt et al 13 analyzed leukapheresis yields in 100 myeloma patients who had received cyclophosphamide 7 g/m 2 followed by G-CSF. In all, 90 patients achieved the target collection of more than 2 Â 10 6 CD34 þ progenitor cells/kg in one leukapheresis session. In an earlier study, the same investigators had shown that this dose of cyclophosphamide was superior to 4 g/m 2 in mobilizing stem cells, even though 63% of patients in the later group achieved successful collection. 14 In the present study, a multivariate analysis showed that the percentage of bone marrow plasma cells and prior administration of radiation therapy significantly predicted for poor mobilization. Demirer et al 12 also found these two factors (as well as the number of prior regimens received) to be predictive of poor mobilization. On multivariate analysis, Goldschmidt et al 14 could not identify strong predictors of mobilization failure, although patients with prior radiation therapy or melphalan tended to mobilize more poorly. Prior use of alkylating agents such as melphalan, although marginally predictive in our multivariate analysis, has been shown by Tricot et al 15 and Prince et al 16 to predict poor mobilization in myeloma patients. We suspect that the small number of patients in our study who had previously received this agent, combined with the generally short duration of preceding therapy, blunted the effect of this drug on mobilization potential. This reflects the greater awareness among our referring physicians of melphalan as a stem cell toxin. Cyclophosphamide plus etoposide was associated with a (EBMT complete plus partial plus minimal ) response rate of 55.6% in our study. However, the regimen was toxic, with 75% of patients requiring hospitalization, 70.5% of patients developing neutropenic fever, and 67% of patients requiring platelet transfusions for severe thrombocytopenia. It is interesting to note that the overwhelming majority of bacteremic episodes in our patients were due to Gram-positive normal flora, which we suspect may have gained access to the blood through central catheters or damaged mouth or bowel mucosa. Dimopoulos et al 17 were the first to report using a combination of cyclophosphamide and etoposide for the treatment of MM, although the doses and schedule used (600 mg/m 2 cyclophosphamide plus 180 mg/m 2 etoposide daily Â 5 days) were different from ours. In a group of 52 patients with advanced or VAD-refractory myeloma, this regimen resulted in a response (X75% M protein reduction, disappearance of Bence Jones protein and decrease of bone marrow plasmacytosis to o5% for X2 months) of 42%. Neutropenic fever occurred in 49/52 (94%) of patients, and two died of that complication. Severe thrombocytopenia (o20 Â 10 9 /l) occurred in 65% of patients. These results are similar to ours.
All of the 77 patients in our study were able to undergo ASCT, receiving a median of 7.03 (range 1.1-25.6) or 7.92 (1.96-38.24) million CD34 þ progenitor cells/kg in the cyclophosphamide or cyclophosphamide plus etoposide group, respectively. As expected, this number of cells resulted in prompt neutrophil and platelet count recovery following transplant in almost all patients. Thus, we could not identify any factors that predicted the tempo of engraftment.
Our study suffers from several limitations. Patients were not randomly assigned to cyclophosphamide or cyclophosphamide plus etoposide, so that comparisons between the two groups have limited applicability. In addition, because these patients proceeded to receive ASCT at an average of 6 weeks after mobilization chemotherapy, it was not possible to observe the duration or maximal effect of chemotherapy achieved by the mobilization regimen. The method of progenitor cell collection (CD34 þ cell tracking followed by large volume leukapheresis) was highly efficient, thus blunting the effect of some pre-treatment variables on mobilization yield. Nevertheless, this study confirms previous reports of cyclophosphamide plus growth factor as a useful regimen for the mobilization of progenitor cells for autologous transplantation, and showing that the regimen is also associated with a remarkable disease response. The addition of etoposide provides at least as many progenitor cells and perhaps a better antimyeloma effect; unfortunately, however, it was clearly more toxic. Future studies should address the contribution of pre-ASCT disease bulk reduction on event-free and survival rates, and should aim at reducing the severe toxicities associated with this approach to mobilization.
